Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

redict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Note: Data in this release correspond to ASH Abstract 904.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th ... laboratory which has developed the AMAS cancer test, is making ... Chicago.  To date, the test, which is a serum-based in ... is emerging as a significant tool in the fight against ... With an estimated 17 million cancer survivors in ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... , July 28, 2014 Southern ... Tipton , Ph.D., President and CEO of Southern ... Controlled Release Society (CRS) for the 2014-2015 term.  ... meeting on July 12 in Chicago ... countries.  The Controlled Release Society ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
(Date:7/28/2014)... Maureen Salamon ... News) -- Infants and children who are at risk ... be vaccinated against the infection, according to updated recommendations ... And routine vaccinations for the potentially deadly ... American Academy of Pediatrics says. In its first ...
(Date:7/28/2014)... News) -- British researchers report that an alternative to ... In their experiments, the scientists found that clasping ... person to the other than what is known as ... might suffice as a cultural substitute for the firm ... the August issue of the American Journal of ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4
... in post-menopausal women after they stopped taking combined hormone ... will be reported in the March 5 edition of ... Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical ... the study. , This latest study reinforces the original ...
... N.C., March 4 DARA BioSciences(TM),(Nasdaq: DARA ... Drutz, MD to the,Board of Directors. Dr. Drutz ... serve on the Company,s Compensation Committee as well ... effective February,26, 2008., Richard Franco, Sr., DARA,s ...
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), today announced it ... 2008, after the U.S. markets close. ISTA will,host a ... and provide a commercial and pipeline update at 5:00 ... live conference call, U.S. and Canadian participants may,dial 866-831-6270; ...
... Initiative points to continued need for mammograms , , TUESDAY, ... cancer lingers after a woman stops taking combination hormone replacement ... in the March 5 issue of the Journal of ... the landmark Women,s Health Initiative (WHI). That trial was halted ...
... 2,500 researchers and professionals in the area of biomolecular science ... Conference & Exhibition of the Society for Biomolecular Sciences (SBS) ... advances in biotechnology, challenges and automation solutions in the field. ... years meeting include: , New Methods ...
... March 4 Perrigo Company,(Nasdaq: PRGO ; ... 20 mg,Omeprazole delayed released tablets to its retail ... same dose as Prilosec OTC(R). Under terms,of an ... is,the exclusive marketer and distributor for the store ...
Cached Medicine News:Health News:LA BioMed researcher says 'unexpected' increase in cancer risk found 2Health News:DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Specialists in drug discovery and development convene 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3
The DSL-10-3000 ACTIVE Ferritin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of ferritin in serum....
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
Medicine Products: